Mitapivat Met Hemoglobin Goal in Sickle Cell Phase 3, But Only 40.6% of Patients Responded
Mitapivat met hemoglobin goal in sickle cell Phase 3, with 40.6% of patients responding and showing significant transfusion burden...
Talquetamab Plus Darzalex Shows 30-Point Progression-Free Survival Gain in Multiple Myeloma
Talquetamab plus Darzalex achieved 81.3% progression-free survival at 24 months in Phase 3 multiple myeloma trial, a 30-point improvement...
What the PRAC’s June 2026 Valproate Meeting Highlights Actually Say About Paternal Exposure Risk
EMA's PRAC found paternal valproate exposure evidence "inconsistent" with causal NDD risk in offspring — but still recommended precautionary...
Nurix’s Bexobrutideg Shows 22.1-Month PFS in Heavily Pretreated CLL
Nurix's bexobrutideg demonstrates 22.1-month median progression-free survival in heavily pretreated CLL patients, including those with BTK resistance mutations.
Spatial CRISPR Screening Just Made Your Preclinical Models Look Like Guesswork
Nature Biotechnology's Perturb-DBiT maps CRISPR perturbations in native tissue — and exposes why dissociated-cell screens keep producing trials that...
CytoDyn Starts Phase 2a Trial of Leronlimab in Early Alzheimer’s Disease
CytoDyn starts Phase 2a trial of leronlimab in early Alzheimer's disease, using PET imaging to measure microglial activation and...
Budoprutug Shows Response in Rituximab-Experienced ITP Patients
Budoprutug shows response in rituximab-experienced ITP patients in Phase 1b data, with three of four prior-treated patients achieving durable...
TransCon PTH Shows 82% Response Rate in 5-Year Hypoparathyroidism Trial
TransCon PTH achieved 82% response rate in a 5-year hypoparathyroidism trial, with 95% of patients completing the study and...
Cemsidomide Shows 53% Response Rate in Heavily Pretreated Myeloma
Cemsidomide shows 53% response rate in heavily pretreated myeloma patients, with responses deepening over time and manageable safety profile...
Ziftomenib Plus Chemotherapy Shows 94% Survival in NPM1-Mutant AML
Ziftomenib plus chemotherapy achieves 94% twelve-month survival in newly diagnosed NPM1-mutant AML patients in the KOMET-007 trial.